Ga-67 uptake: A predictor of post-therapy active residual disease and clinical outcome in patients with diffuse large cell lymphoma
| Autor: | Sari, I., Kula, M., Eser, B., Kaynar, L., Altuntaş, F., Koçyigit, I., Mavili, E. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
survival rate
Lymphoma large B-cell diffuse cancer patient gallium 67 doxorubicin vincristine computer assisted tomography male Neoplasm residual cancer relapse human cancer survival outcome assessment large cell lymphoma adult article imaging scoring system treatment response Gallium citrate major clinical study predictor variable aged female risk factor prednisone histopathology minimal residual disease cyclophosphamide prognosis |
| Popis: | Purpose: Diagnosis and treatment of post-therapy active residual disease (PTARD) is essential in patients with lymphoma. After treatment, Ga-67 scan is considered as a useful technique for monitoring response in these patients. Material and Methods: Between December 1998 and January 2004, 63 patients histopathologically diagnosed with Diffuse Large Cell Lymphoma (DLCL) were studied. Patients were evaluated before and after treatment with a whole body Ga-67 scan in addition to other imaging techniques. International Prognostic Index (IPI), and clinical variables were determined according to criteria reported by the International non-Hodgkin's Lymphoma Prognostic factors Project. Results: Among the patients with positive computed tomography (CT) scan, the 5-year relapse-free and overall survival rates were 70% and 78% for those with negative scans compared with 23% and 35% for gallium-positive patients, respectively (p< 0.004, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|